Laura A. Vogel
Partner
Duane Morris LLP
100 High Street, Suite 2400
Boston, MA 02110-1724
USA
Phone: +1 857 488 4284
Fax: +1 857 401 3045
Email: lavogel@duanemorris.com

Laura A. Vogel practices in the area of intellectual property law with an emphasis on litigating complex patent matters. Ms. Vogel is a registered patent attorney representing high-tech and generic pharmaceutical companies (ANDA) in both opinion and litigation matters. Ms Vogel's practice also includes counseling clients on intellectual property strategy; preparing validity, infringement, freedom-to-operate, and patentability opinions; carrying out due diligence investigations and evaluating patent portfolios. Ms. Vogel has significant experience in representing clients in interferences before the United States Board of Patent Appeals and Interferences, as well as in the preparation and prosecution of U.S. and foreign patent applications in the areas of biotechnology, food sciences and molecular and cellular biology, recombinant DNA technology, therapeutic proteins, diagnostic assays, gene therapy, vaccines and tissue sealant technology.

Admitted to practice in Massachusetts, New York and the District of Columbia and before the U.S. Patent and Trademark Office, Ms. Vogel is a 2002 graduate of Tulane Law School, where she was senior business editor of Tulane Journal of Technology and Intellectual Property, and a cum laude graduate of the University of New Hampshire (University Honors; Honors in Major). Her Honors Thesis was entitled "The Effects of Tissue Inhibitors of Metalloproteinases on Progesterone Production in the Bovine Corpus Luteum."

Areas of Practice

• Intellectual Property
• Patents
• Trial

Representative Matters

• King Pharmaceuticals, Inc. et al. v. Actavis Inc., et al., Case No. 07-05041 (D.N.J. – G. Brown). Represented Actavis in ANDA litigation regarding AVINZA®, the active ingredient of which is morphine sulfate.
• Pfizer Inc., et al. v. Mylan Pharmaceuticals, Inc., Case No. 10-00085 (D.Del. – J. Farnan). Represented Mylan in ANDA litigation involving Pfizer's cardiovascular product CADUET®, the active ingredients of which are atorvastatin calcium and amlodipine besylate. Settled prior to trial.
• Shire LLC, et al. v. Sandoz Inc., No. 11-CV-01110 (RBJ)(KMT) (D. Col.) Patent infringement action regarding Sandoz's ANDA to make a generic version of Shire’s ADHD product Intuniv®, the active ingredient of which is guanfacine hydrochloride.
• Genentech, et al. v. Sandoz, Case No. 11-CV-1925 (N.D.Cal. – J. White). Representing Sandoz in ANDA litigation regarding VALCYTE®, the active ingredient of which is valganciclovir.
• Medicis Pharmaceutical Corp. v. Sandoz Inc., et al., Case No. 09-033 (JJF) (D Del.). Patent infringement action regarding Sandoz's ANDA to make a generic version of Medicis's acne product Solodyn®, the active ingredient of which is minocycline hydrochloride.
• Sepracor Inc. v. Teva Pharmaceuticals USA, Inc., et al., Case No. 09-CV-1302 (DMC)(D NJ). Patent infringement action regarding Wockhardt USA LLC's ANDA to make a generic version of Sepracor's insomnia product Lunesta®, the active ingredient of which is eszopiclone.
• Sanofi-Aventis US LLC v. Barr Laboratories Inc., Case No. 06-CV-286 (D Del). Patent infringement action regarding Barr Laboratories' ANDA to make a generic version of sanofi's nasal allergy product Nasacort® AQ, the active ingredient of which is triamcinolone.
• Endo Pharmaceuticals Inc. et al. v. Sandoz, Inc., Case Nos. 08-534 and 08-970 (KSH) (D Del.). Patent infringement action regarding Sandoz's ANDA to make a generic version of Endo's pain product Opana® ER, the active ingredient of which is oxymorphone hydrochloride.
• Wyeth v. Apotex Inc., and Apotex Corp., Case No. 08-022308 (S.D. Fla.). Patent infringement action regarding Apotex's ANDA to make a generic version of Wyeth's anti-depressant product EFFEXOR® XR, the active ingredient of which is venlafaxine hydrochloride.
• Aventis Pharma S.A. and Sanofi-Aventis U.S. LLC v. Apotex Inc. and Apotex Corp., Case No. 08-496 (GMS) (D. Del. 2010). Patent infringement action regarding Apotex's ANDA to make a generic version of Sanofi-Aventis' anti-cancer product TAXOTERE®, the active ingredient of which is docetaxel. Following a two-week trial, obtained an order for Apotex striking down the patents-in-issue as invalid and unenforceable due to Sanofi-Adventis' inequitable conduct in procuring the patents.

Professional Activities

• Massachusetts Bar Association
• Boston Patent Law Association
• Women in BIO

Admissions

• Massachusetts
• District of Columbia
• New York
• U.S. Patent and Trademark Office
• U.S. Court of Appeals for the Federal Circuit

Education

• Tulane Law School, J.D., 2002
• University of New Hampshire, B.S., Animal Science: Pre-Veterinary Medicine, cum laude, 1997

Experience

• Duane Morris LLP
  - Partner, 2012-present
  - Associate, 2008-2011
• Sterne, Kessler, Goldstein & Fox, P.L.L.C.
  - Associate, 2002-2008

Selected Publications

• "Two Big Wins for Generics Clarify Non-Infringement Strategies for Method of Use Patents," Genericsweb INNsight, May, 2012
• "U.S. Supreme Court Restores Generic Pharma's Ability to Challenge Orange Book Use Code Information," Duane Morris Alert, April 19, 2012

Selected Speaking Engagements

• Participant, American Conference Institute's Paragraph IV Disputes Conference, New York City, April 23, 2012
• Speaker, "Patent Reform Act of 2007 Or 2008?? Or 2009??" Georgetown University Law Center, Student Intellectual Property Law Association, February 2008